For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Fibrogen, Inc.

USPTO Granted Patents = 89

CIPO Patents = 7

EPO Patents = 38

Trademarks = 5

Forward Citations = 934

Loading Chart...

Loading Chart...

78 inventors (with patents filed for the assignee):

Michael P Arend (37 out of 37 patents)

Lee Allen Flippin (32 out of 45 patents)

Volkmar Guenzler-Pukall (27 out of 27 patents)

4. Thomas B Neff (27 out of 27 patents)

5. Stephen J Klaus (21 out of 21 patents)

6. Eric Douglas Turtle (21 out of 28 patents)

7. Wen-Bin Ho (19 out of 20 patents)

8. Todd W Seeley (17 out of 20 patents)

9. Ingrid Langsetmo Parobok (13 out of 13 patents)

10. Xiaohui Du (11 out of 47 patents)

11. Christopher J Molineaux (10 out of 10 patents)

12. Robert C Stephenson (10 out of 10 patents)

13. Jung Min Park (10 out of 10 patents)

14. Michael D Thompson (10 out of 11 patents)

15. David A Yeowell (10 out of 16 patents)

Core Competencies:

Erythropoiesis

Iron Metabolism

HIF Hydroxylase Inhibitors

Prolyl Hydroxylase Inhibitors

Nitrogen-Containing Heteroaryl Compounds

Idiopathic Pulmonary Fibrosis

Stroke Treatment

Pancreatic Cancer

Isoquinoline Compounds

Naphthyridine Derivatives

Thiochromene Derivatives

Muscular Dystrophy

89 patents: Sort by Forward Citations

1. 11680048 - Enhanced erythropoiesis and iron metabolism (2023-06-20),

2. 11680047 - Enhanced erythropoiesis and iron metabolism (2023-06-20),

3. 11299537 - Methods for treatment of motor neuron diseases (2022-04-12),

4. 11229637 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2022-01-25),

5. 10927081 - Enhanced erythropoiesis and iron metabolism (2021-02-23),

6. 10894774 - Enhanced erythropoiesis and iron metabolism (2021-01-19),

7. 10882827 - Enhanced erythropoiesis and iron metabolism (2021-01-05),

8. 10765672 - Pharmaceutical formulations of a HIF hydroxylase inhibitor (2020-09-08),

9. 10646482 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2020-05-12),

10. 10626090 - Enhanced erythropoiesis and iron metabolism (2020-04-21),

11. 10555713 - Methods for treating idiopathic pulmonary fibrosis (2020-02-11),

12. 10272078 - Crystalline forms of a prolyl hydroxylase inhibitor (2019-04-30),

13. 10118897 - Crystalline forms of a prolyl hydroxylase inhibitor (2018-11-06),

14. 10092558 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2018-10-09),

15. 10039515 - Methods for treating idiopathic pulmonary fibrosis (2018-08-07),

FibroGen, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics for the treatment of serious unmet medical needs. With a strong pipeline of investigational drugs, FibroGen is committed to discovering and developing therapies that improve the lives of patients with various diseases, including anemia, fibrosis, and cancer. Through cutting-edge science and rigorous clinical research, FibroGen is dedicated to making a positive impact in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

89 Patents

#71 in San Francisco, CA

#967 in California

#4,049 in US

#8,344 in the World

San Francisco, CA, United States of America

Fibrogen, Inc.

Forward Citations = 934

78 inventors:

Michael P Arend (37 out of 37 patents)

Lee Allen Flippin (32 out of 45 patents)

Volkmar Guenzler-Pukall (27 out of 27 patents)

4. Thomas B Neff (27 out of 27 patents)

5. Stephen J Klaus (21 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…